153 related articles for article (PubMed ID: 36852868)
1. Kaempferol suppresses glioma progression and synergistically enhances the antitumor activity of gefitinib by inhibiting the EGFR/SRC/STAT3 signaling pathway.
Zhou J; Liu Y; Chen J; Xiong N; Yi D
Drug Dev Res; 2023 May; 84(3):592-610. PubMed ID: 36852868
[TBL] [Abstract][Full Text] [Related]
2. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
[TBL] [Abstract][Full Text] [Related]
3. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.
Wang S; Wang Y; Huang Z; Wei H; Wang X; Shen R; Lan W; Zhong G; Lin J
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1670-1680. PubMed ID: 34693451
[TBL] [Abstract][Full Text] [Related]
4. Acetylshikonin exerts anti-tumor effects on non-small cell lung cancer through dual inhibition of STAT3 and EGFR.
Tang Y; Wang Y; Wang X; Zhao Z; Cai H; Xie M; Jiang X; Zhang L; Cheng J; Yang L; Wang L; Zhao C; Huang X
Phytomedicine; 2022 Jul; 101():154109. PubMed ID: 35526322
[TBL] [Abstract][Full Text] [Related]
5. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
6. Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
Jin H; Jiang AY; Wang H; Cao Y; Wu Y; Jiang XF
Mol Med Rep; 2017 Sep; 16(3):3475-3481. PubMed ID: 28713965
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of gefitinib derivative LPY‑9 on human glioma.
Sun Y; Chu L; Wang H; Peng H; Liu J
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34212976
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT3 signaling contributes to the anti-melanoma effects of chrysoeriol.
Liu YX; Chen YJ; Xu BW; Fu XQ; Ding WJ; Li SA; Wang XQ; Wu JY; Wu Y; Dou X; Liu B; Yu ZL
Phytomedicine; 2023 Jan; 109():154572. PubMed ID: 36610164
[TBL] [Abstract][Full Text] [Related]
9. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
10. Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3.
Dai Z; Wang L; Wang X; Zhao B; Zhao W; Bhardwaj SS; Ye J; Yin Z; Zhang J; Zhao S
Oncol Rep; 2018 Aug; 40(2):867-876. PubMed ID: 29989652
[TBL] [Abstract][Full Text] [Related]
11. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
12. Kaempferol inhibits non-homologous end joining repair via regulating Ku80 stability in glioma cancer.
Chen M; Zhao E; Li M; Xu M; Hao S; Gao Y; Wu X; Li X; Yu Y; Yu Z; Yin Y
Phytomedicine; 2023 Jul; 116():154876. PubMed ID: 37210962
[TBL] [Abstract][Full Text] [Related]
13. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
14. Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway.
Yao S; Wang X; Li C; Zhao T; Jin H; Fang W
Tumour Biol; 2016 Aug; 37(8):10247-56. PubMed ID: 26831667
[TBL] [Abstract][Full Text] [Related]
15. AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways.
Lai YH; Lin SY; Wu YS; Chen HW; Chen JJW
J Hematol Oncol; 2017 Nov; 10(1):172. PubMed ID: 29132432
[TBL] [Abstract][Full Text] [Related]
16. Bergaptol inhibits glioma cell proliferation and induces apoptosis via STAT3/Bcl-2 pathway.
Huang H; Zhang J; Wu J; Du C; Zheng B; Guo Z; Chen L; Zhang D; Liu L
Anticancer Drugs; 2024 Jul; 35(6):535-541. PubMed ID: 38527238
[TBL] [Abstract][Full Text] [Related]
17. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
Yuan S; Xu Y; Yi T; Wang H
J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
[TBL] [Abstract][Full Text] [Related]
18. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
Meco D; Servidei T; Riccardi A; Ferlini C; Cusano G; Zannoni GF; Giangaspero F; Riccardi R
Neuro Oncol; 2009 Jun; 11(3):250-9. PubMed ID: 19033425
[TBL] [Abstract][Full Text] [Related]
20. Gallic acid suppresses colon cancer proliferation by inhibiting SRC and EGFR phosphorylation.
Lin X; Wang G; Liu P; Han L; Wang T; Chen K; Gao Y
Exp Ther Med; 2021 Jun; 21(6):638. PubMed ID: 33968169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
